Gland Pharma Limited (NSE: GLAND) reported Revenue from Operations of ₹938.28 Crore down from ₹1,063.32 Crore year on year, a decline of 11.8%. Consolidated Net Profit of ₹231.94 Crore, slumped 15% from ₹273 Crore in the same quarter of the previous year. The Earnings per Share is ₹14.08 for this quarter.
Gland Pharma Limited Q3 FY23; Net Profit Down To 232 Crore
Related Post
- Kellton Tech Solutions Limited posts double-digit Q3 FY26 growth as digital transformation drives revenue; margins improve
Kellton Tech Solutions Limited (NSE: KELLTONTEC, BSE: 519602) reported double-digit year-on-year growth in revenue and…
-
Inox Green Energy Services Limited approves Q3 FY26 results and reappoints whole-time director
Inox Green Energy Services Limited (NSE: INOXGREEN, BSE: 543667) said its board approved the unaudited…
-
Huhtamaki India Limited reports flat Q4 2025 sales as margins improve on favorable mix and efficiency gains
Huhtamaki India Limited (NSE: HUHTAMAKI, BSE: 509820) reported broadly flat revenue in the fourth quarter…